10/11/2006 | BT | S&P: Pharmaceutical sales growth spurs mergers
|
9/19/2006 | BT | Schering, Organon end collaboration on male birth control
|
9/15/2006 | BT | Schering, AstraZeneca form alliance to develop breast cancer drug
|
7/31/2006 | BT | Schering's phase 3 trial of sargramostim for Crohn's disease fails to meet two primary endpoints
|
7/25/2006 | BT | Schering net sales for the first six months of 2006 up 11% to €2.824 billion
|
7/14/2006 | BT | Schering, Avid to develop early diagnostic imaging approach for Alzheimer's disease
|
7/13/2006 | BT | EPIX retains full rights to EP-2104R; Schering decides not to exercise option
|
7/11/2006 | BTCV | S&P cuts Bayer, Schering
|
6/26/2006 | BT | NexMed: Schering AG terminates its license for Alprox-TD for erectile dysfunction
|
6/21/2006 | BT | Celera sells cathepsin S inhibitor program to Schering
|
6/14/2006 | BT | Bayer to buy Merck's 21.8% stake in Schering at €89, Bayer drops lawsuit
|
6/13/2006 | BT | Bayer purchases 530,471 Schering shares in open market, privately negotiated trades
|
6/7/2006 | BT | Schering's Betaferon approved in Europe as a first-line treatment for earliest stages of multiple sclerosis
|
6/1/2006 | BT | Merrill Lynch neutral on CCR5 drugs
|
5/23/2006 | BT | Schering AG starts phase 2 trials of epothilone, ZK-EPO, in breast, ovarian cancer
|
5/2/2006 | BT | Schering gets positive opinion on Betaferon for early use in multiple sclerosis patients
|
4/18/2006 | BT | Schering's executive, supervisory boards recommend acceptance of Bayer takeover offer
|
3/24/2006 | BT | Bayer offers to acquire Schering for €86 a share in a deal worth €16.3 billion
|
3/17/2006 | BT | Schering receives FDA approval for low-dose oral contraceptive YAZ
|
3/14/2006 | BT | Moody's may downgrade Schering
|
3/13/2006 | BTCV | S&P puts Merck, Schering on negative watch
|
3/13/2006 | BT | Merck announces €14.6 billion takeover offer for Schering
|
2/23/2006 | BT | Schering AG boosted to outperform by Bear Stearns
|
2/23/2006 | BT | Schering to divest radiopharmaceutical business of CIS Bio International
|
2/21/2006 | BT | S&P: Schering unaffected
|
2/10/2006 | BT | Schering exercises option with EPIX to develop preclinical gadofluorine derivative
|
1/25/2006 | BT | Schering: FDA won't require further studies on YAZ for premenstrual disorder
|
1/4/2006 | BT | FDA approves Berlex's Climara Pro hormone patch to prevent postmenopausal osteoporosis
|
12/20/2005 | BT | Schering to raise dividend by 20%
|
12/13/2005 | BT | Schering to sell 50% interest in ALK-Scherax
|
12/12/2005 | BT | Schering to promote Jenapharm brand name, integrate research, sell plant
|
12/9/2005 | BT | Schering granted extended review period by FDA for YAZ oral contraceptive
|
12/5/2005 | BT | Schering considers alternatives for radiopharmaceutical business
|
11/30/2005 | BT | Schering begins three phase 2 trials with anti-cancer compound ZK-EPO
|